The Myeloma Beacon ran a story this morning about Pfizer’s PD 0332991 Phase 1 study:
Experimental Drug PD 0332991 Shows Encouraging Phase 1 Trial Results In Relapsed/Refractory Multiple Myeloma Patients (ASH 2010).
Something about PD 0332991 sounded familiar. So I typed it into the blogger query locator box, located in the upper left hand corner of the page. Like magic–there is was: Tuesday, November 30, 2010 –
I had forgotten to do a follow-up story. Thanks, Michelle Spektor, for writing an article about PD 0332991 so I don’t have to!
My thoughts? Looks like PD 0332991 may become another new secondary, combination therapy option for multiple myeloma patients. This isn’t the “big one,” the cure we have been looking for. It probably isn’t a Revlimid or Velcade, either. But it is an oral therapy, which is nice. We should learn more about just how effective it is as the next Stage 2 study moves forward.
Feel good and keep smiling! Pat